{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:23:46Z","timestamp":1771640626047,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1994,7]]},"abstract":"<jats:p>Thor\u00e9n MC, Wivall-Helleryd I-L. Blum WF, Hall KE. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol 1994;131:33\u201340. ISSN 0804\u20134643<\/jats:p>\n        <jats:p>Insulin-like growth factor I (IGF-I) circulates bound to specific binding proteins (BPs) that modulate its effects at target cells. Hypoglycemia alters the serum levels of insulin-dependent IGFBPs and thus modifies the IGF-I action. We administered recombinant IGF-I (40 \u03bcg\/kg body wt, from Kabi Pharmacia) in a morning dose (08.00 h) for seven consecutive days to six patients (21\u201347 years) with panhypopituitarism. This dose did not lead to hypoglycemia. Repeated blood sampling was performed on days 1 and 7, otherwise morning samples were drawn. The mean serum total IGF-I was maximal 3\u20134 h after the injection. A higher peak and basal value (p &lt; 0.05) was observed on day 7 when compared to that observed on day 1. The concentrations were 237 vs 190 \u03bcg\/l and 43 vs 22 \u03bcg\/l. The mean free IGF-I increased concomitantly to 17 and 20 \u03bcg\/l after 2\u20133 h on days 1 and 7. After 4 h, IGF-II was decreased (p &lt;0.05) from 340 to 291 \u03bcg\/l on day 1 and from 341 to 252 \u03bcg\/l on day 7. The IGF-I area under the curve on days 1 and 7 was correlated to the IGFBP-3 levels. Only the patient with the highest IGFBP-3 level obtained IGF-I levels above 100 \u03bcg\/l for 24 h. In spite of unchanged glucose levels, there was a modest suppression of insulin levels (p &lt; 0.05) between 0 and 4 h from 102 to 78 pmol\/l on day 1 and from 90 to 60 pmol\/l on day 7 when the subjects were fasting. A small decline of mean potassium concentrations was found 2\u20136 h after the injection on day 1. During a week with daily injections, the morning serum IGF-I increased slightly in comparison to basal levels but no significant change in morning values of IGFBP-1, -2, -3, glucose and insulin were observed. Serum urea, creatinine, cholesterol and free fatty acid decreased significantly, indicating metabolic effects of IGF-I. Thus IGF-I has metabolic effects in doses not leading to hypoglycemia. To achieve a normal diurnal IGF-I level, recombinant IGF-I should be administered two or three times per 24 h in subjects with subnormal IGFBP-3 levels.<\/jats:p>\n        <jats:p>Marja Thor\u00e9n, Department of Endocrinology and Diabetology, Karolinska Hospital, S-171 76 Stockholm, Sweden<\/jats:p>","DOI":"10.1530\/eje.0.1310033","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T21:19:42Z","timestamp":1229375982000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":18,"title":["Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency"],"prefix":"10.1093","volume":"131","author":[{"given":"Maria C","family":"Thor\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga-Lena","family":"Wivall-Helleryd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner F","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin E","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/131\/1\/eje_131_1_006.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/131\/1\/eje_131_1_006.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:19:19Z","timestamp":1676391559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/131\/1\/33\/6750791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,7]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje.0.1310033","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,7]]}}}